Atorvastatin 40mg
DrugEach tablet will be taken once daily for 84 days.
Other names: Lipitor
NCT Number: NCT06248671
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Phase 2
Haukeland University Hospital, Bergen, Norway
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
After the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer attacks than 4 or more than 14 per month, the baseline period can be extended to 8 weeks, and the patient can be randomized to a treatment then if there is a mean of 4-14 attacks per 4 weeks during the 8-week's period.
Exclusion criteria
Each tablet will be taken once daily for 84 days.
Other names: Lipitor
Each tablet will be taken once daily for 84 days
Each tablet will be taken once daily for 84 days.
Other names: Lipitor
Time frame: 4 weeks
Change in number of migraine days/4 weeks from the baseline period to the treatment period.
Time frame: 12 weeks
Number of responders (≥ 50% improvement from baseline)
Time frame: 12 weeks
Number of patients with adverse events
Time frame: 12 weeks
Doses of triptans or analgesics per 4 weeks
Time frame: 12 weeks
Days with sick leave per 4 weeks
Contact information is provided by the study sponsor or research team.
Joakim H Østhus, Cand.med.
CONTACT
Lise R Øie, Post.doc.
CONTACT
St. Olavs Hospital
Other
EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine
Acronym: EStatinMig
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06603558
Brain Diseases, Central Nervous System Diseases
Busan, Busan Gwang Yeogsi, South Korea
View Trial DetailsNCT06229834
Brain Diseases, Central Nervous System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07103694
Brain Diseases, Central Nervous System Diseases
Milan, Italy
View Trial DetailsNCT07159750
Brain Diseases, Central Nervous System Diseases
Miami, Florida, United States
View Trial Details